0000000000086282

AUTHOR

P. Bidoli

showing 1 related works from this author

Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the s…

2015

Oncologymedicine.medical_specialtybusiness.industryHistologySubgroup analysisHematologyPlaceboStage IV non-small cell lung cancerSurgeryRamucirumabDouble blindSecond lineOncologyDocetaxelInternal medicinemedicinebusinessmedicine.drug
researchProduct